Загрузка...
Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD‐1) inhibitors have been reported to show antitumor effects in patients with high programmed death‐ligand 1 (PD‐L1) expressing SC, the...
Сохранить в:
| Опубликовано в: : | Thorac Cancer |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons Australia, Ltd
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8017259/ https://ncbi.nlm.nih.gov/pubmed/33605089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13890 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|